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Abstract
Background: Pancreatic cancer is the fourth leading cause of cancer related deaths in America. Monoclonal antibodies are a
viable treatment option for inhibiting cancer growth. Tumor specific drug delivery could be achieved utilizing these
monoclonal antibodies as targeting agents. This type of designer therapeutic is evolving and with the use of gold
nanoparticles it is a promising approach to selectively deliver chemotherapeutics to malignant cells. Gold nanoparticles
(GNPs) are showing extreme promise in current medicinal research. GNPs have been shown to non-invasively kill tumor cells
by hyperthermia using radiofrequency. They have also been implemented as early detection agents due to their unique X-
ray contrast properties; success was revealed with clear delineation of blood capillaries in a preclinical model by CT
(computer tomography). The fundamental parameters for intelligent design of nanoconjugates are on the forefront. The
goal of this study is to define the necessary design parameters to successfully target pancreatic cancer cells.
Methodology/Principal Findings: The nanoconjugates described in this study were characterized with various physico-
chemical techniques. We demonstrate that the number of cetuximab molecules (targeting agent) on a GNP, the
hydrodynamic size of the nanoconjugates, available reactive surface area and the ability of the nanoconjugates to sequester
EGFR (epidermal growth factor receptor), all play critical roles in effectively targeting tumor cells in vitro and in vivo in an
orthotopic model of pancreatic cancer.
Conclusion: Our results suggest the specific targeting of tumor cells depends on a number of crucial components 1)
targeting agent to nanoparticle ratio 2) availability of reactive surface area on the nanoparticle 3) ability of the
nanoconjugate to bind the target and 4) hydrodynamic diameter of the nanoconjugate. We believe this study will help
define the design parameters for formulating better strategies for specifically targeting tumors with nanoparticle
conjugates.
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Introduction
Cancer claims nearly 25% of deaths annually. Pancreatic cancer
is the fourth leading cause of cancer related deaths in America, in
both men and women. Despite vast efforts to detect and treat
pancreatic cancer, the incidence and mortality rates remain
virtually the same. Early diagnosis and efficient delivery of
therapeutic agents to malignant cells remain the two major
challenges in cancer management strategies [1].
Monoclonal antibodies against growth factor receptors have
been shown to be viable treatments for inhibiting cancer growth
[2]. Utilizing these monoclonal antibodies as targeting agents for
tumor specific delivery is evolving as a promising approach to
selectively deliver chemotherapeutics [3]. Inorganic nanomaterials
are being studied as the delivery vehicle for targeted drug delivery.
Gold nanomaterials are of particular interest due to the unique
physico-chemical and optoelectronic properties, ease of synthesis
and surface modification [1,4,5,6,7,8,9,10,11,12,13].
Gold nanoparticles (GNPs) have recently been used to kill
tumor cells by hyperthermia using non-invasive radiofrequency
[14]. Their utility as a contrast agent has also been demonstrated
by clear delineation of blood capillaries in a preclinical model by
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20347CT (computer tomography) in comparison to the conventional
iodine based contrast agents [15]. Both studies are hopeful and
their utility is further encouraged by the safety profile [16,17].
Epidermal growth factor receptor (EGFR) is an important
target in cancer research. It is overexpressed in a number of
human malignancies including pancreatic cancer. Human EGFR
is a transmembrane glycoprotein [3,18,19,20]. It consists of an
extracellular ligand binding domain, a hydrophobic transmem-
brane domain and an intracellular tyrosine kinase domain. Ligand
binding to EGFR induces receptor homo/heterodimerization
leading to the phosphorylation of tyrosine residues. Phosphoryla-
tion of EGFR activates complex down stream signaling events
leading to proliferation, migration, invasion, and inhibition of
apoptosis of cancer cells [21,22,23].
The monoclonal anti-EGFR antibody, Cetuximab (C225), is a
unique targeting agent to target EGFR-positive cancer cells.
Cetuximab was approved by the FDA for the treatment of
patients with EGFR positive colorectal cancer (CRC) [21,22,23].
It has also been either approved or is in different phases of clinical
trials in many other malignancies such as NSCLC (non small cell
lung carcinoma), SCCHN (squamous cell carcinoma of the head
and neck) and pancreatic cancer [24,25,26]. Cetuximab is a
chimeric human:murine immunoglobulin G1 (IgG1) monoclonal
antibody (MoAb). The binding of C225 to EGFR leads to
receptor internalization and degradation without receptor phos-
phorylation, thus inhibiting EGFR-associated pathways [24,
25,26].
Despite the emerging utility of GNPs in targeted delivery
fundamental questions remain unanswered. What are the design
criteria for fabricating nanoconjugates that will ensure maximum
uptake in cancer cells? Herein, we utilize cetuximab (C225) as a
targeting agent and GNP as a model system. We demonstrate that
the number of C225 antibodies on a GNP (C225:GNP ratio), the
hydrodynamic size, the available reactive surface area and the
ability of the nanoconjugate to sequester EGFR, all play critical
roles in effectively targeting tumor cells in vitro and in vivo in an
orthotopic model of pancreatic cancer. Uptake studies with the
isotype control, GNP-IgG, indicate that the specificity of tumor
cell targeting is dependent on the nanoparticle surface coverage by
C225. Non-specific uptake decreases when the C225 to GNP ratio
increases. These studies are critical to develop an efficient targeted
delivery system for future clinical use.
The work presented herein shows the systematic characteriza-
tion of GNP-C225 nanoconjugates. The specific targeting
potential was investigated, both in vitro and in vivo in an orthotopic
model of pancreatic cancer. Our results demonstrate that the
hydrodynamic radius, accessible reactive surface area and loading
capacity of C225 on GNPs play critical roles for efficient targeting
of tumor cells. These findings highlight key parameters to be
considered for a promising nanoparticle based drug delivery
system for future clinical application.
Results
Characterization of the nanoconjugates with variable
antibody to nanoparticle ratios
In order to understand the parameters required for specific
targeting of nanoconjugates to tumor cells, we selected cetuximab
(C225) as a targeting agent. C225 is a chimeric human-murine
monoclonal antibody that binds to the extracellular domain of
EGFR [3]. EGFR is overexpressed in a number of human
malignancies including pancreatic cancer, rendering it an
attractive target [18]. To determine the optimum valency of
C225 on GNPs (the number of C225 molecules per GNP and
hence C225:GNP ratio) for intracellular uptake, we synthesized
various nanoconjugates with multiple C225:GNP ratios. Charac-
terization of these nanoconjugates was performed using several
physicochemical techniques: UV-Visible (UV-Vis) spectroscopy,
transmission electron microscopy (TEM), dynamic light scattering
(DLS) and radioiodination of C225 with
125I. The GNPs used in
this study were synthesized by sodium borohydride reduction of
tetrachloroaurate [27,28]. As previously reported, the presence of
a surface plasmon resonance band at ca. 510 nm confirms the
formation of spherical gold nanoparticles (Figure S1). The
Figure 1. Determination of binding capacity and stability of GNP-C225 conjugates. a. Change in absorption maxima as a function of
increasing concentration of C225 in absence (spheres) and presence of NaCl (triangles). b. Concentration of C225 bound to GNP as a function of
increasing concentration of C225, determined by measuring the concentration of free C225 labeled with I125 in the supernatant, after pelleting down
the GNP-C225 conjugates by ultracentrifugation.
doi:10.1371/journal.pone.0020347.g001
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further confirmed by TEM (data not shown).
The GNP-C225 conjugates were then synthesized using this
naked GNP solution and purified as described in the materials and
methods section. The antibody spontaneously binds to the GNPs
through Au-S and Au-N bonding [19]. The production of GNP-
C225 was monitored by UV-Vis spectroscopy. It is evident that
with the addition of C225 there is a gradual red shift in the SPR
band of the naked gold, from 510 nm to 519 nm (Figure 1a). Such
a red shift in the SPR band of the GNPs suggests the perturbation
of the electrical double layer by the antibody surrounding the
GNPs and thus indicates binding of the antibody to the
nanoparticles [29,30].
To further confirm the GNP-C225 conjugation we challenged
the nanoconjugates against salt induced aggregation (critical
coagulation concentration). Addition of 140 mM NaCl has been
reported to result in aggregation of naked or partially covered
particles, such aggregation leads to a dramatic red shift in the SPR
band. The absorption spectra of the nanoconjugates were
recorded 15 minutes after incubation with 140 mM of sodium
chloride (NaCl). As expected, the naked GNPs showed a drastic
red shift in the SPR band from 510 nm to around 600 nm
(Figure 1a) confirming aggregation of uncovered nanoparticles
[31]. Salt induced aggregation was directly related to the increased
loading of C225 on the GNP surface, hence the SPR band
completely disappeared at a C225 to GNP ratio of 3 (three C225
molecules per GNP) suggesting the absence of available reactive
surface to salt induced aggregation.
Quantification of C225 binding to gold nanoparticles by
radioiodination
The binding of C225 to GNPs was quantified using radiola-
belled
125I-C225. A fixed concentration of GNPs was incubated
with
125I-C225 at various C225:GNP ratios. The conjugates were
centrifuged at high speed (45000 g) for 1 hour to separate the
unbound antibody from the nanoconjugates. The efficiency of the
GNP-C225-I
125 binding was then determined by measuring the
emission of gamma rays emanating from the free and bound
125I-
C225 in the supernatant and the pellet fractions, respectively. As
shown in Figure 1b and Figure S2, there was a very high binding
percentage of C225 (,90%) to GNPs up to a ratio of 3 (3 C225
molecules per GNP). However, a minimal increase in binding is
observed above a ratio of 3. This small increase at high antibody
concentrations might be due to weak nonspecific protein-protein
interactions between the bound and free antibody. This data
further corroborates the observations made by UV-Vis spectros-
copy discussed above; where the extent of salt induced aggregation
was found to be minimal at a ratio of 3.
Targeted delivery of gold nanoparticles to pancreatic
cancer cells in vitro
To understand the role of multivalency on the intracellular
uptake by human pancreatic cancer cell lines with variable EGFR
expression, we treated AsPC-1, PANC-1 and MiaPaca-2 cells with
GNP-C225 or nonspecific isotype control GNP-IgG at different
antibody to GNP (Ab:GNP) ratios. EGFR expression in these cells
follows the order AsPC-1$PANC-1.MiaPaca-2 [19]. The
amount of cellular uptake for GNP-C225 and GNP-IgG by the
different cell lines was quantified by determining the gold content
in the cells through instrumental neutron activation analysis
(INAA). Figures 2a, 2b and 2c represent the gold content of AsPC-
1, PANC-1 and MiaPaca-2 cells, respectively. It is evident from
the figures that the uptake of the nanoconjugates in all three cell
lines gradually increases with the increasing C225:GNP ratio
(increased valency). The maximum uptake was observed with the
1.5 ratio (black bars); beyond this ratio the uptake of the
nanoconjugates gradually decreased. The uptake trend of the
nanoconjugates follows a similar pattern in all three cells lines. It is
also important to note that the extent of uptake was much less for
the corresponding ratios for isotype controls, GNP-IgG (grey bars).
Interestingly, the non-specific uptake of GNP-IgG gradually
decreased with increasing IgG:GNP ratio where minimum uptake
was observed at the ratio of 3. It is likely that at the lower Ab:GNP
ratio, the available free reactive surface area on the GNP can non-
specifically bind either to the serum proteins or cell membranes or
both; which in turn could promote the non-specific uptake of the
nanoconjugates. Adsorption of serum components is known to
influence the uptake of GNP [32]. Increasing Ab:GNP ratios
should increase the antibody coverage of the nanoparticle surface,
thus providing less open surface area available for non-specific
interactions. Reduction of such non-specific interactions might
explain reduced uptake of GNP-IgG conjugates observed at higher
ratios (Figure 2).
Internalization of the nanoconjugates by pancreatic
cancer cells in vitro
To further confirm the intracellular uptake and localization of
GNPs, TEM analysis was performed after treating the cells with
the same nanoconjugates used for the uptake studies. Figure 3
shows TEM micrographs of AsPC-1 cells after treatment with
GNP-C225 at varying C225:GNP ratios. Low, medium and high
Figure 2. Uptake of GNP-Ab conjugates by pancreatic cancer cells. a. AsPC-1 Cells, b. PANC-1 cells, c. MiaPaca-2 cells, treated with GNP-C225
(black bars) or GNP-IgG (grey bars) prepared at different Ab:GNP ratios. Y axis represents Gold concentration as ppm of total dry mass of cells.
doi:10.1371/journal.pone.0020347.g002
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0.38, 1.5 and 3.0 (Figure 3). The nanoconjugates are shown within
the vesicular structures of the cells, confirming intracellular uptake
of the nanoconjugates. Similar results were also obtained with
PANC-1 and MiaPaca-2 cells (Figures S3, S4). The differential
uptake of the GNPs by the cancer cells having different
C225:GNP ratios might also be due to the differential affinity of
the nanoconjugates to bind EGFR, or size of the nanoconjugates.
Interestingly, when the same cell lines were treated with GNP-
IgG, the isotype control, most of the GNPs are found at the
periphery of the cell membrane with minimal endocytosis (Figure
S5). This is consistent with a recent report describing the targeting
of a solid tumor with transferrin coated GNPs [33].
Hydrodynamic diameter of the nanoconjugates and their
ability to sequester EGFR
In an attempt to elicit the mechanism for differential uptake of
GNP-C225, we hypothesized that the different C225:GNP ratios
possess differential ability to bind EGFR. To validate this
hypothesis, we performed western blot analysis. The various
GNP-C225 and GNP-IgG conjugates were incubated with AsPC-
1 cell lysates for 2 h, then centrifuged at high speed. The pellet was
washed once and then the supernatant and pellet were subjected to
western blot analysis to detect the relative presence of EGFR in the
different fractions. The results are shown in Figure 4a. This clearly
demonstrates there is a progressive depletion of EGFR in the
supernatant with an increasing C225:GNP ratio (middle panel).
Also interesting to note an enrichment of EGFR in the pellet
fraction (upper panel) reaching a plateau at a ratio of 1.5–2.29,
most likely a function of C225 loading on the pellet surface. b-
actin levels were used as loading controls demonstrating equal
loading of protein in different lanes. It is also important to note
that when the same lysates were treated with GNP-IgG, hardly
any detectable EGFR was found in the pellet fraction, mostly it
was found in the supernatant fraction, further confirming the
binding specificity of GNP-C225 to EGFR. Together, this data
suggests that the GNP-C225 conjugates can specifically sequester
EGFR from the cell lysates and the sequestering ability increases
with an increasing number of C225 molecules on the GNP
surface.
The ability of the nanoconjugates to sequester EGFR with a
C225:GNP ratio of 1.5 to 3 is similar; however, the in vitro
Figure 3. Internalization of different GNP-C225 conjugates by AsPC-1 Cells. TEM images at different magnifications, showing
internalization of GNP-C225. Please see Figures S3 and S4 for TEM images illustrating GNP-C225 internalization by PANC-1 and MiaPaca-2 cells.
doi:10.1371/journal.pone.0020347.g003
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To explain the decreasing uptake of the nanoconjugates with an
increasing C225:GNP ratio, we investigated the role of the
hydrodynamic diameter of the nanoconjugates. The hydrody-
namic diameter (HD) of the conjugates was determined through
dynamic light scattering spectroscopy (DLS) measurements
(Figure 4b). Recently, HD has been shown to be critical for
tumor targeting of quantum dots [34]. Furthermore, it has also
been demonstrated that the in vitro cellular uptake and response is
dependent on the size of the nanoconjugates. Upon conjugation
with a 0.38 C225:GNP ratio the HD of the GNPs immediately
increases from 7 nm to 21 nm, further confirming the binding of
C225 to the GNP surface [35]. The HD remains around 21 nm
until a ratio of 2.29 then sharply increases at a ratio of 3. It
should be noted from Figures 1b and S2 that nearly all antibody
molecules remain bound to the GNP surface up to a ratio of 3.
However, there is only a gradual increase in binding above this
ratio, most likely attributed to nonspecific binding. This
nonspecific binding of antibody molecules may be causing the
formation of a loose secondary layer around GNP-C225 resulting
Figure 4. Characterization and in vitro uptake of GNP-C225. a. Binding of GNP-C225 and GNP-IgG to EGFR verified by Western Blot analysis.
Cell lysates from AsPC-1 cells were incubated for 2 hrs at room temperature with GNP-C225 and GNP-IgG conjugates with various ratios of antibody
on the surface of the particle. After incubation the samples were spun at high speed and the supernatant was collected and the pellet was washed
once and respun; the nanoconjugate fraction was 20 times the concentration of the supernatant. The pellet and the supernatant fractions were
loaded on a 7.5% SDS-PAGE gel and analyzed for EGFR. b. Hydrodynamic diameter of GNP-C225 measured by Dynamic Light Scattering
Spectroscopy.
doi:10.1371/journal.pone.0020347.g004
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sharp increase in HD could also be due to the heterogeneity of
the sample. Obtaining a discrete number of antibody molecules
per GNP is very difficult to achieve experimentally. The
relationship between the multivalency of the nanoparticles to
their hydrodynamic diameters needs to be further investigated.
TEM analysis confirmed that the sharp increase in the HD is not
due to aggregation of the nanoparticles. The TEM micrographs
did not show any significant aggregation of the nanoparticles with
different C225:GNP ratios (Figure S6).
Delivery of GNP-C225 in an orthotopic model of
pancreatic cancer
To further investigate the ability of these nanoconjugates to
specifically target tumor cells in vivo, we utilized an orthotopic
pancreatic cancer model. The model was generated after
surgically implanting AsPC-1 cells expressing luciferase into the
pancreas of nude mice and allowed to grow for 12 days. Every
third day the mice were injected with 200 ml of ketamine and
100 ml of luciferin and imaged for tumor growth progression by
bioluminiscence measurments. This orthotopic model tries to
mimic the human pathogenesis of pancreatic cancer [36] and
allows tumor cells to experience the effects of the microenviron-
ment in the pancreas. On day 12, GNP-C225 and GNP-IgG
were administered i.p. to study tumor uptake and distribution of
nanoconjugates having different Ab:GNP ratios. The mice were
sacrificed 24 h after nanoconjugate injection and the tumors and
other vital organs were collected for determination of gold
content by INAA. Figure 5a shows a representative example of a
bioluminescence image of mice 12 days after orthotopic
implantation of the tumor cells into the pancreas (upper panel).
Strong bioluminescence suggests the formation and growth of a
tumor in the pancreas. Tumor growth was further confirmed by
measuring the tumor size at the end of the experiments after
sacrificing the mice (lower panel). The tumor size measured using
the formula ab
2/2 (a=length, b=width) was ,62 mm
3 when
nanoconjugates were administered for biodistribution studies.
Figure 5b shows the tumor uptake of GNP-C225 and GNP-IgG
at varying Ab:GNP ratios as a function of gold content
determined by INAA. The in vivo and in vitro tumor uptake of
the nanoconjugates followed a similar pattern. Statistical analysis
using the two-tailed students t-test demonstrated that the uptake
of GNP-C225 with a ratio of 0.76 and 1.5 were significantly
higher than the ratio of 3 (p,0.05). Furthermore, the uptake of
the GNP-C225 conjugates was significantly higher (p,0.05) than
the isotype control, GNP-IgG at all ratios except 3. As mentioned
earlier, the HD of GNP-C225 remained constant from a ratio of
0.38 to 2.29 (around 21 nm) but dramatically increased at a ratio
of 3 (134 nm). Theoretically, the larger HD of the nanoconju-
gates at a ratio of 3 could contribute to lower diffusion and in
turn reduction in uptake [37]. This illustrates that the HD is a
critical factor for in vivo uptake and consequently a key factor for
active targeting. To further investigate the intratumoral (inside
the cells; or in the vasculature or in the capsule outside of the
tumor tissue) location of the nanoconjugates, we performed TEM
on the tumor tissues shown in figure 5a, which were obtained
after sacrificing the mice 24 h post intraperitoneal administration
of different nanoconjugates. Figure 6 shows the location of GNPs
in different areas of the tumor tissues in case of GNP-C225
(C225:GNP 3.0 (Figure 6a and b) and 1.5 (Figure 6c) treated
groups. It is evident that GNPs are inside the cells (Figure 6a, left
and right panels are images of the same area, different
magnification) as well as the capsule covering the tumor tissue
(Figure 6b, left and right panel are images of the same area,
different magnification). However, the nanoconjugates are mostly
localized outside of the tumor tissue in case of the GNP-IgG
treated group (IgG:GNP 1.5) (Figure S7).
The presence of injected conjugates in other major organs was
also determined by INAA (Figure S8). Gold uptake was also found
in other organs, such as spleen, liver, lung, kidney and brain
[38,39].
Discussion
Targeted delivery of inorganic nanomaterials is an essential
area of research for nanomedicine. Unique physicochemical
properties of inorganic nanomaterials may be utilized for several
biomedical applications such as detection/diagnosis, therapy and
imaging. Thus, it is important to define the design parameters to
specifically deliver nanoconjugates to the cells of interest. There
are several key factors that may define the success of targeted
delivery; (i) selection of an appropriate model to study the
delivery approach; (ii) selection of an effective targeting agent;
(iii) optimization of the number of targeting agents per
nanoparticle; (iv) availability of free reactive area on the particle
surface that may initiate non-specific binding; (v) ability of the
targeting agent to sequester the target and (vi) hydrodynamic size
of the nanoconjugates.
Most of the delivery strategies are tested in non-orthotopic
models where tumors are generated away from the original site. A
major advantage to this model is tumors are easy to develop and
growth can be monitored by manual measurement with slide
calipers. A disadvantage of this model is that the tumor cells do not
experience a true tumor microenvironment. In contrast, the
orthotopic model implants tumor cells in the organ of tumor
origin, rendering it a more realistic model. Thus, we selected the
orthotopic model to study the design parameters necessary for
nanoconjugates to successfully and specifically target a tumor.
We selected cetuximab as a targeting agent and gold
nanoparticles as the scaffold for targeting delivery. One of the
major advantages to utilizing gold nanoparticles is their formation
of stable bonds with biomolecules such as organothiols, organoa-
mines, proteins, and antibodies [5]. We demonstrated the
significant binding of cetuximab to GNPs up to a ratio of 3.
(C225:GNP=3) beyond which only a marginal increase in
binding is observed. This marginal increase might be due to the
lack of free reactive surface area remaining on the GNPs. The
nature of bonding between gold and proteins has been the subject
of intense investigation over the last several decades. It is now
generally accepted that there are three main types of interactions
that occur between a protein/antibody and a gold nanoparticle; (i)
electrostatic interactions of negatively charged GNPs with
positively charged proteins; (ii) covalent interactions between the
thiol/amine groups present within amino acid residues in
antibodies and the GNPs; and (iii) hydrophobic interactions
between proteins and GNPs [19,40]. Using X-ray photoelectron
spectroscopy and thermogravimetric analysis we previously
demonstrated that cetuximab utilizes thiol and amine functional-
ities to bind to the surface of gold nanoparticles [19,40].
It is also imperative to validate the design parameters for
different cell lines with variable expression of the target receptor.
This is particularly important considering the heterogeneous
nature of tumors. In these studies we employed three different
pancreatic cancer cell lines with variable expression of EGFR. We
also demonstrated that intracellular uptake of GNP-C225 is not
only dependent on the number of cetuximab molecules, but also
depends on their ability to bind EGFR, as well as the
hydrodynamic size of the nanoconjugates. It is also evident that
Targeted Delivery in Pancreatic Cancer
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coverage of the targeting agent on the nanoparticle surface.
Maximum specific uptake of GNP-C225 is observed when there
are three C225 molecules on a GNP even though the overall
uptake is reduced. This data further demonstrates the combined
importance of the number of targeting agents per particle and the
hydrodynamic size of the nanoconjugates. This is also reflected in
the difference between the specific uptake of GNP-C225 and the
non-specific uptake of GNP-IgG.
Recently, several groups have been focusing on understanding
the design parameters for efficiently targeting tumors with
nanoconjugates in a preclinical model. It has also been reported
Figure 5. Characterization of AsPC-1 orthotopic tumor growth and in vivo Au uptake in the tumors. a. Bioluminescence images on day
12 depicting tumor presence (top panel) and digital camera images (bottom panel) of tumor masses excised after termination of the mice above. The
mice were sacrificed on day 13, 24 hrs after nanoconjugate treatments. b. In vivo tumor uptake of GNP-C225 and GNP-IgG conjugates at varying
ratios of antibody; 24 h after the intraperitoneal injection of the conjugates into an orthotopic model of pancreatic cancer. The uptake was
determined by measuring the gold concentration in the tumors by INAA. Y axis represents gold concentration as ppm.
doi:10.1371/journal.pone.0020347.g005
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targeting tumor cells [41]. Antibody targeted liposomes have
been found to exert enhanced efficacy over their non-targeted
counterparts [42]. Furthermore, delivery of siRNA using trans-
ferring-targeted polymeric nanoparticles demonstrated better
efficacy even though their kinetics, biodistribution and tumor
uptake was similar [43]. Similar observations were also made in
a study of transferrin-coated gold nanoparticles; it was
demonstrated that ligand content on the nanoparticles are
important for targeting [33]. Here, we explore an orthotopic
model of pancreatic cancer and in turn, demonstrate the critical
roles that the number of antibody molecules on the GNP, the
ability of the nanoconjugates to bind the target receptor, the
availability of the reactive surface for non-specific interaction
and the hydrodynamic size of the nanoconjugates all play in
efficient design.
Taken together our data suggests that the specific targeting of
tumor cells depends on a number of important factors; 1) targeting
agent to nanoparticle ratio; 2) availability of the reactive surface
area on the nanoparticle; 3) ability of the nanoconjugate to bind
the target and 4) hydrodynamic diameter of the nanoconjugate.
Thus, intelligent design for successful targeting of tumor cells
requires optimization of these crucial factors. We believe this study
will help define the design parameters for formulating better
strategies for specifically targeting tumors with nanoparticle
conjugates.
Materials and Methods
Synthesis and characterization of GNP-antibody
conjugates
The naked GNPs were synthesized by reduction of 100 ml of
0.1 mM HAuCl4 (Aldrich) solution with 50 ml of a freshly
prepared aqueous solution containing 4.3 mg of sodium borohy-
dride (Aldrich) under constant stirring, overnight at ambient
temperature. The GNPs were characterized by transmission
electron microscopy (TEM) after drop-coating 100 ml of the
sample on a carbon-coated copper grid. The size of the
nanoparticles was determined from analysis of the TEM images.
The GNP-antibody conjugates were synthesized by mixing the
desired antibody (C225 or IgG) with the naked GNP solution.
C225 is purchased in a solution of 2 mg/ml (ErbituxTM Injection,
ImClone Inc and Bristol-Myers Squibb Co.) and human IgG was
purchased in a solution of 10.0–11.2 mg/ml (Jackson Immuno
Research Laboratories, Inc.). These solutions were diluted in water
to a 1 ml final volume with the desired mgs present and then added
drop wise to 100 ml of naked GNPs. This solution was stirred
vigorously at ambient temperature for 2 hrs. The mixture was
then centrifuged at 22,000 rpm in a Beckman Ultracentrifuge in a
50.2 Ti rotor to separate the desired GNP-antibody from
unconjugated antibody. The conjugates formed a loose pellet at
the bottom of centrifuge tube and were collected after careful
removal of the supernatant. The gold concentration of the
conjugates was determined from absorbances obtained by UV-
Visible spectrometry (UV 2401PC, Shimadzu Corp) at 500 nm
(A500), taken before and after centrifugation and by instrumental
neutron activation analysis (INAA).
Determining the number of C225 molecules bound to a
GNP
Aliquots of C225 were labeled to a high specific activity using
the chloramine-T procedure. 500 mg of C225 was diluted to a final
volume of 200 ml with 100 mM phosphate buffer, pH 7.4. Then
1.0 mCi (10 ml) carrier free Iodine-125 radionuclide was added to
the antibody solution. Immediately thereafter, 100 mg chloramine-
T (100 mlo f1 0mg/ml diluted in phosphate buffer, pH 7.4) was
added and incubated for 2 minutes with intermittent vortexing.
The reaction was quenched with the addition of 500 mg of sodium
metabisulfite (100 mlo f5 0 mg/ml diluted in phosphate buffer,
pH 7.4). The final product was dialyzed against PBS in a 1000
MWCO dialysis membrane (Spectra/Por 7) overnight at 4uC with
two changes of 500 ml phosphate buffered saline pH 7.4. The
specific activity of the labeled antibody was determined by the
TCA (trichloroacetic acid) precipitation method. In brief, 5 mlo fa
1:200 dilution of the original labeled mixture was mixed with
100 ml of BSA and precipitated with 200 ml TCA. The mixture
was centrifuged for 5 minutes at 15000 g. Radioactivity in the
precipitate and supernatant were counted in a Packard gamma
(Packard, Cobra D5003) counter. The labeled preparation was not
used for further studies if the labeled antibody was ,99%. The
protein concentration in the labeled antibody stock was deter-
mined by the bicinchoninic acid (BCA) method.
Different amounts of labeled C225 were added to a solution of
GNPs and incubated for 2 hours as described above. The
conjugates were then centrifuged at 45000 g for 1 hour in a
Beckman Ultra using a TL100.2 rotor. The radioactive emission
from 10 ml of the pellet and supernatant was measured in a
gamma counter as described above. The emission from the
original labeled protein and the supernatant after centrifugation
were used to calculate the concentration of C225 bound to GNP
surface.
Cell culture and treatments
Pancreatic cancer cell lines: AsPC-1, PANC-1 and MiaPaca-2
were grown in RPMI and Dulbecco’s Modified Eagles medium
(Gibco) supplemented with 10% fetal bovine serum (Gibco) and
1% antibiotics (Pen/Strep) at 37uC, in a humidified chamber
under 20% O2 and 5% CO2 environment until confluent. The
cells were incubated with different GNP-Ab conjugates at a final
concentration of 50 mg/ml of gold for 2 hours followed by a rinse
with PBS to remove non-bound conjugates. The cells were
trypsinized and pelleted in a centrifuge at 1300 rpm for 5 minutes.
The cell pellets were washed twice with PBS and analyzed for gold
content by INAA or fixed in Trumps solution for TEM analysis.
Measurement of gold content by Instrumental Neutron
Activation Analysis (INAA)
Samples were analyzed by instrumental neutron activation
analysis at the University of Missouri Research Reactor Center as
previously described. Briefly, tissues and cell pellets were prepared
by weighing the samples into high-density polyethylene irradiation
vials and lyophilized to a dry weight. Solution samples were
preparedbygravimetricallytransferring100 mltoanirradiationvial
followed by lyophilization. All samples were loaded in polyethylene
transfer ‘‘rabbits’’ in sets of nine and irradiated for 90 s in a thermal
Figure 6. Representative TEM images of tumor sections illustrating nanoconjugate location within the tumor tissue. a and b.
GNP-C225 with the 3.0 ratio of Ab:GNP are shown on the left in a low magnification to show a large surface area of tumor tissue and on the right the
magnification is increased to elucidate the internalization of the conjugates themselves. c. GNP-C225 with the 1.5 ratio of Ab:GNP are shown on the
left in low magnification to show a large surface area of tumor tissue and on the right the magnification is increased to reveal the conjugates
themselves inside cellular space.
doi:10.1371/journal.pone.0020347.g006
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13 nc m
22 s
21. The samples
were then allowed to decay for 24 to 48 h and counted on a high-
purity germanium detector for 3600 s at a sample-to-detector
distance of approximately 5 cm. The mass of gold in each sample
was quantified by measuring 411.8 keV gamma ray from the b
2
decay of
198Au (t1/2=2.7 days). The area of this peak was
determined by the Genie ESP spectroscopy package from
Canberra. A minimum of six geometrically equivalent comparator
standards werealso run. The standards were prepared by aliquoting
approximately 0.1 (n=3) and 0.01 (n=3) mg of gold from a
(10.060.5) mg/mL certified standard solution (High-Purity Stan-
dards) in the polyethylene irradiation vials, and were used with each
sample set.
Dynamic Light Scattering Spectroscopy (DLS)
Determination of the hydrodynamic (HD) diameter of the
GNP-C225 conjugates was determined by DLS in a Zetasizer
instrument (Nano ZS, Malvern Instruments Ltd) equipped with a
633 nm LASER.
Transmission electron microscopy (TEM)
TEM samples involving cells were prepared as described
previously [29,40]. In brief, cells were treated with gold
nanoconjugates for 2 h in the presence of serum. After the
incubation, cells were washed thrice in PBS and cell pellets
collected after trypsinization and centrifugation at 1500 rpm for
5 minutes. The resultant cell pellets were further washed thrice
with PBS, and fixed in Trumps fixative (1% glutaraldehyde and
4% formaldehyde in 0.1 M phosphate buffer, pH 7.2) and
processed for TEM sectioning as previously described. Micro-
graphs were taken on a TECNAI 12 operating at 120 KV.
TEM samples from the extracted mice tumors were prepared as
follows; on day 13 the mice (n=3) were sacrificed and the tumors
were collected, weighed, measured and placed immediately in
trumps fixative solution and stored on ice. The tumors were briefly
removed from the trumps solution and sliced thinly for TEM
mounting. Micrographs were taken on a TECNAI 12 operating at
120 KV.
EGFR pull down/depletion assay
To determine the binding of the conjugates to EGFR, 100 mlo f
AsPC-1 cell lysates (containing 1.8 mg/ml of total protein) was
incubated with 100 ml of 100 ug/ml GNP-C225 and GNP-IgG at
various ratios of antibody for 2 hrs at ambient temperature. The
mixtures were then centrifuged at 30,000 rpm for 1 h. The
supernatant was removed and saved. The remaining pellet was
washed with 100 ml of water and respun for 1 h at 30,000 rpm.
The second supernatant was removed and saved. 20 mlo f2 6
SDS-PAGE loading dye was added to the pellet and 10 ml the
initial supernatant was taken and 10 ml2 6 SDS-PAGE loading
dye was added. All samples were placed in a 95uC heating block
for 5 minutes and subsequently loaded to a 7.5% SDS-PAGE gel.
The gel was run for 45 mins at 150 V and then were transferred to
a PVDF membrane and blotted for EGFR with an anti-EGFR
antibody against its c-terminal region (Santa Cruz).
Animal handling and in vivo tumor uptake
For the generation of orthotopic pancreatic tumor models,
1.5610
6 AsPC-1 cells were injected into the pancreas of nude
mice. Every third day the mice were injected with 200 mlo f
ketamine and 100 ml of luciferin and imaged for tumor growth
progression. Twelve days after tumor cell implantation, the mice
were randomly distributed into 6 groups (n=3). GNP-C225 and
GNP-IgG conjugates at a gold concentration of 220 mg/ml was
injected i. p. to each mouse. The mice were sacrificed 24 hrs after
the injection and the tumor mass along with other organs and
blood were collected and analyzed for gold content.
Statistical analysis
Statistical analysis was done by a two-tailed student t-test and a
value of P,0.05 was considered to be significant.
Supporting Information
Figure S1 Representative absorption spectrum of the
GNP used in the study.
(TIF)
Figure S2 Binding of C225 to GNP determined by I
125
labeled C225: Concentration of C225 bound to GNP with
increasing concentration of C225 represented as the fraction of
total C225 added.
(TIF)
Figure S3 Internalization of different C225-GNP conju-
gates by Panc-1 Cells. Representative TEM images at different
magnifications showing internalization of C225-GNP conjugates.
(TIF)
Figure S4 Internalization of different C225-GNP conju-
gates by MiaPaca-2 Cells. Representative TEM images at
different magnifications showing internalization of C225-GNP
conjugates.
(TIF)
Figure S5 Internalization of GNP-IgG conjugates by
PANC-1 and MiaPaca-2 Cells. Representative TEM images at
different magnifications showing internalization of GNP-IgG
conjugates.
(TIF)
Figure S6 TEM images of GNP-C225 conjugates syn-
thesized at different C225:GNP ratio. Figure a, b, c and d
are the representative images of GNP-C225 conjugates synthe-
sized at ratio 0.76, 1.52, 2.29 and 3.76 respectively.
(TIF)
Figure S7 Representative TEM images of tumor sec-
tions illustrating nanoconjugate location outside the
tumor tissue. GNP-IgG with the 1.5 ratio of Ab:GNP are
shown on the left and right (in a low magnification and high
magnification, respectively) to illustrate the accumulation of the
non-specific nanoconjugates outside of the tumor tissue.
(TIF)
Figure S8 In vivo gold uptake in 5 vital organs
determine by INAA. In vivo uptake of GNP-C225 conjugates
(at varying ratios of antibody) by vital organs; 24 hrs after the
intraperitoneal injection of the conjugates into an orthotopic
model of pancreatic cancer. The uptake was determined by
measuring the gold concentration in the tumors by INAA. Y axis
represents gold concentration as ppm.
(TIF)
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